EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieKohortenstudie

Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score–adjusted retrospective cohort study

Héctor Pinargote-Celorio iD, Óscar Moreno-Pérez iD, Pilar González-De-La-Aleja iD, Jara Llenas-García iD, Pedro María Martínez Pérez-Crespo iD, Juan-Carlos Rodríguez-Díaz iD, Belén Martínez-López iD, Nicolás Merchante Gutiérrez iD, José-Manuel Ramos-Rincón iD, Esperanza Merino iD

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae351 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Héctor Pinargote-Celorio und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious Diseases, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain. Hauptthemen laut MEDLINE: Immunocompromised Host, Antiviral Agents, COVID-19 Drug Treatment, SARS-CoV-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The effectiveness of the early treatment for antiviral agents in SARS-CoV-2 infection is closely related to patient comorbidities. Data on effectiveness in immunocompromised patients are limited, with reports involving highly heterogeneous and not well-defined populations. We aimed to assess the effectiveness of treatment in reducing hospitalizations in a real-world cohort of severely immunocompromised COVID-19 outpatients. Patients and methods We conducted a multicentre, retrospective, observational cohort study of immunocompromised outpatients attended in infectious diseases departments from 1 January to 31 December 2022. Propensity score matching (PSM) multivariable logistic regression models were used to estimate the adjusted odds ratio [(aOR, 95% confidence interval (CI)] for the association between antiviral prescription and outcome (COVID-19–related hospitalization up to Day 90).

Results

We identified 746 immunocompromised outpatients with confirmed SARS-CoV-2 infection. After eligibility criteria and PSM, a total of 410 patients were analysed: 205 receiving treatment (remdesivir, sotrovimab or nirmatrelvir/ritonavir) and 205 matched controls. Fifty-two patients required at least one COVID-19–related hospitalization 8 (3.9%) versus 44 (21.5%) in the antiviral and matched control cohorts, respectively. There were 13 deaths at 90 days, of which only 4 were COVID-19–related and none in the antiviral treatment group. After adjustment for residual confounders, the use of early therapy was associated with a protective effect on the risk of hospitalization [aOR 0.13 (0.05–0.29)], as was the use of biological immunomodulators [aOR 0.27 (0.10–0.74)], whereas chronic obstructive pulmonary disease [aOR 4.65 (1.09–19.69)] and anti-CD20 use [aOR 2.76 (1.31–5.81)] increased the odds.

Conclusions

Early antiviral treatment was associated with a reduced risk of COVID-19–related hospitalization in ambulatory severely immunocompromised COVID-19 patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunocompromised HostAntiviral AgentsCOVID-19 Drug TreatmentSARS-CoV-2Propensity ScoreCOVID-19OutpatientsHospitalizationHumansMaleFemaleRetrospective StudiesMiddle AgedAgedRitonavirTreatment OutcomeAlanineDrug CombinationsLopinavirAdultAdenosine Monophosphate

Substanzen

Antiviral AgentsRitonavirremdesivirAlanineDrug CombinationsLopinavirlopinavir-ritonavir drug combinationAdenosine Monophosphate

Autor:innen und Institutionen

  • Unit of Infectious Diseases, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
  • Endocrinology Department Dr. Balmis General University Hospital, Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain.
  • Clinical Medicine Department, University Miguel Hernández of Elche, Sant Joan d'Alacant, Alicante, Spain.
  • Internal Medicine Service Vega Baja Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Valencia, Spain.
  • CIBER of Infectious Diseases (CIBERINFEC), Carlos III Health Institute, Madrid, Spain.
  • Clinical Unit of Infectious Diseases and Microbiology, Valme University Hospital, Sevilla, Spain.

ORCID-Profile: Héctor Pinargote-Celorio, Óscar Moreno-Pérez, Pilar González-De-La-Aleja, Jara Llenas-García, Pedro María Martínez Pérez-Crespo, Juan-Carlos Rodríguez-Díaz, Belén Martínez-López, Nicolás Merchante Gutiérrez, José-Manuel Ramos-Rincón, Esperanza Merino

Zitieren

APA

Pinargote-Celorio, H., Moreno-Pérez, Ó., González-De-La-Aleja, P., Llenas-García, J., Martínez Pérez-Crespo, P. M., Rodríguez-Díaz, J. C., Martínez-López, B., Merchante Gutiérrez, N., Ramos-Rincón, J. M., & Merino, E. (2024). Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score–adjusted retrospective cohort study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae351

Vancouver

Pinargote-Celorio H, Moreno-Pérez Ó, González-De-La-Aleja P, Llenas-García J, Martínez Pérez-Crespo PM, Rodríguez-Díaz JC, et al. Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score–adjusted retrospective cohort study. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae351

BibTeX
@article{PinargoteCelorio2024,
  author = {Pinargote-Celorio, Héctor and Moreno-Pérez, Óscar and González-De-La-Aleja, Pilar and Llenas-García, Jara and Martínez Pérez-Crespo, Pedro María and Rodríguez-Díaz, Juan-Carlos and Martínez-López, Belén and Merchante Gutiérrez, Nicolás and Ramos-Rincón, José-Manuel and Merino, Esperanza},
  title = {Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score–adjusted retrospective cohort study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae351}
}
Kostenlos starten →